Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > CFTR modulator therapy alters sphingolipid profiles in blood from people with cystic fibrosis

CFTR modulator therapy alters sphingolipid profiles in blood from people with cystic fibrosis

Resource Type

CF Research News

Authors

Dirk Westhölter, Fabian Schumacher, Nuria Wülfinghoff, Sivagurunathan Sutharsan, Svenja Strassburg, Burkhard Kleuser, Peter A Horn, Sebastian Reuter, Erich Gulbins, Christian Taube1, Matthias Welsner

References

J Cyst Fibros. 2022 Feb 12;S1569-1993(22)00037-6. doi: 10.1016/j.jcf.2022.02.005.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Theme

Nutrition/Gastroenterology [3]

Keywords

CFTR modulator therapy [4]
Ceramide [5]
Elexacaftor/tezacaftor/ivacaftor [6]
Plasma sphingolipids [7]

Date

Saturday, February 12, 2022

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [8]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/cftr-modulator-therapy-alters-sphingolipid-profiles-blood-people

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-21-00456R1_FINAL_Westholter_200322.pdf [2] https://pubmed.ncbi.nlm.nih.gov/35168870/ [3] https://www.ecfs.eu/research-article-themes/nutritiongatroenterology [4] https://www.ecfs.eu/research-article-keywords/cftr-modulator-therapy [5] https://www.ecfs.eu/research-article-keywords/ceramide [6] https://www.ecfs.eu/research-article-keywords/elexacaftortezacaftorivacaftor [7] https://www.ecfs.eu/research-article-keywords/plasma-sphingolipids [8] https://www.ecfs.eu/resource-guideline-type/other-guidelines